The HILOPRO technology uses patented platform technology with GRAS excipients to enable innovator mAbs and biosimilars for SubQ delivery, optimized dosing and enhanced market acceptance.
This single formulation technology works for a wide range of monoclonal antibodies, supports multiple dosing and delivery options providing greater flexibility and optimal patient convenience.
High concentration formulation offers extended release, resulting in long acting protein formulations.
Reduces the frequency of injections.
Low viscosity formulation enables the change of administration from Intravenous (IV) to Subcutaneous (SubQ).
Facilitates the delivery using syringes, autoinjector devices or pens.
(Fixed or variable)
(Type of device
(High concentration - Low volume IV or SubQ)
IV to SubQ
The HILOPRO platform technology enables SubQ delivery of mAbs by formulating,
a high-concentration, low-viscosity, low-volume solution and combining it with an appropriate delivery device like syringe, a wearable device or an autoinjector.
This system approach provides the most convenient and cost effective method of converting IV formulations into SubQ.